Last 1,497 INR
Change Today -33.60 / -2.20%
Volume 116.7K
CDH On Other Exchanges
Symbol
Exchange
Natl India
As of 6:05 AM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

cadila healthcare ltd (CDH) Snapshot

Open
1,523
Previous Close
1,530
Day High
1,560
Day Low
1,445
52 Week High
11/11/14 - 1,760
52 Week Low
01/6/14 - 730.25
Market Cap
306.5B
Average Volume 10 Days
79.0K
EPS TTM
39.25
Shares Outstanding
204.7M
EX-Date
07/17/14
P/E TM
38.1x
Dividend
9.00
Dividend Yield
0.60%
Current Stock Chart for CADILA HEALTHCARE LTD (CDH)

Related News

No related news articles were found.

cadila healthcare ltd (CDH) Related Businessweek News

No Related Businessweek News Found

cadila healthcare ltd (CDH) Details

Cadila Healthcare Limited discovers, develops, manufactures, and markets a range of healthcare products worldwide. It provides its products in various forms, including formulations, injectable, aerosols, ointments, vaccines, biologics, active pharmaceutical ingredients, etc. The company offers products in the areas of cardiovascular, gastro intestinal, respiratory, women’s healthcare, pain management, CNS, anti-infective, oncology, neuroscience, dermatology, nephrology, and chronic/lifestyle primarily under the Aten, Ocid, Deriphyllin, Pantodac, Atorva, Nucoxia, and Mifegest brands. It also provides consumer healthcare and wellness products, such as Sugar Free Gold, a sweetener; Sugar Free Natura, a sucralose based sugar substitute; Sugar Free D’lite, a healthy drink; Nutralite, a cholesterol-free table spread; and Actilife, a nutritional milk additive for adults, as well as skincare products comprising scrubs, peel-off, face wash, and soaps under its Everyuth and Dermacare brands. In addition, the company researches and develops a pipeline of 19 biologics comprising 17 biosimilars and 2 novel biological products; new drugs in cardio-metabolic, inflammation, pain, and oncology therapeutic areas; novel drug delivery systems; molecules for DMF filing and NPD molecules; and generic products, as well as solid orals, pulmonary, parenterals, suppository, topical, and oncology products. Further, it provides animal healthcare products comprising drugs, feed supplements, and vaccines for livestock, companion animals, and poultry. Additionally, the company develops vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, and HPV. It has strategic out-licensing deal with Abbott Laboratories for the commercial supply of products. The company was founded in 1952 and is headquartered in Ahmedabad, India.

Founded in 1952

cadila healthcare ltd (CDH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cadila healthcare ltd (CDH) Key Developments

Cadila Healthcare Ltd Launches Biosimilar for Adalimumab

Cadila Healthcare Ltd. announced the launch of a biosimilar for adalimumab. The drug will be marketed under the brand name Exemptia. They have a similar level of efficacy and safety and provide additional advantage to patients in terms of affordability and accessibility. It is estimated that more than 12 million patients in India suffer from the chronic conditions the drug targets, which progressively deteriorate and lead to lifelong pain and in some cases, disability. The drug will be marketed by Zydus Biovation.

Cadila Healthcare Ltd Announces Resignation of Apurva S. Diwanji as Director

Cadila Healthcare Ltd. announced that the Directors of the Company approved the resignation of Shri. Apurva S. Diwanji as Director. The resignation has been received and taken on record on December 04, 2014.

Cadila Healthcare Limited Announces Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Cadila Healthcare Limited announced unaudited standalone and consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, on consolidated basis, the company reported total income from operations of INR 21,080.0 million, profit from operations before other income, interest and exceptional items of INR 3,477.0 million, profit from ordinary activities before tax of INR 3,452.8 million, net profit of INR 2,881.5 million or basic and diluted EPS before and after extraordinary items of INR 13.58 as compared to total income from operations of INR 17,467.9 million, profit from operations before other income, interest and exceptional items of INR 2,087.8 million, profit from ordinary activities before tax of INR 2,016.8 million, net profit of INR 1,915.7 million or basic and diluted EPS before and after extraordinary items of INR 8.96 for the same period prior year. For the six months, on consolidated basis, the company reported total income from operations of INR 41,581.2 million, profit from operations before other income, interest and exceptional items of INR 6,561.1 million, profit from ordinary activities before tax of INR 6,448.4 million, net profit of INR 5,352.7 million or basic and diluted EPS before and after extraordinary items of INR 25.31 as compared to total income from operations of INR 33,838.4 million, profit from operations before other income, interest and exceptional items of INR 4,474.5 million, profit from ordinary activities before tax of INR 4,250.4 million, net profit of INR 3,946.2 million or basic and diluted EPS before and after extraordinary items of INR 18.48 for the same period prior year. For the quarter, on standalone basis, the company reported total income from operations of INR 12,528.1 million, profit from operations before other income, interest and exceptional items of INR 2,716.9 million, profit from ordinary activities before tax of INR 4,052.5 million, net profit of INR 3,656.1 million or basic and diluted EPS before and after extraordinary items of INR 17.86 as compared to total income from operations of INR 9,849.9 million, profit from operations before other income, interest and exceptional items of INR 1,375.9 million, profit from ordinary activities before tax of INR 1,361.9 million, net profit of INR 1,517.6 million or basic and diluted EPS before and after extraordinary items of INR 7.41 for the same period prior year. For the six months, on standalone basis, the company reported total income from operations of INR 23,656.9 million, profit from operations before other income, interest and exceptional items of INR 4,825.9 million, profit from ordinary activities before tax of INR 6,242.4 million, net profit of INR 5,629.0 million or basic and diluted EPS before and after extraordinary items of INR 27.49 as compared to total income from operations of INR 19,130.9 million, profit from operations before other income, interest and exceptional items of INR 2,828.6 million, profit from ordinary activities before tax of INR 4,864.0 million, net profit of INR 4,919.8 million or basic and diluted EPS before and after extraordinary items of INR 24.03 for the same period prior year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDH:IN 1,496.75 INR -33.60

CDH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 605.50 INR -17.90
Ipca Laboratories Ltd 714.55 INR -11.60
Piramal Enterprises Ltd 777.55 INR -3.50
Ranbaxy Laboratories Ltd 617.45 INR -17.90
Torrent Pharmaceuticals Ltd 1,039 INR +1.75
View Industry Companies
 

Industry Analysis

CDH

Industry Average

Valuation CDH Industry Range
Price/Earnings 31.6x
Price/Sales 3.7x
Price/Book 7.6x
Price/Cash Flow 25.2x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.